The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer

Overview

Journal Am J Med Sci

Publisher Elsevier

Specialty General Medicine

Date 2020 May 30

PMID 32466856

Citations 13

Authors

Chenghao Yang

Xiaoyu Jia

Jinbao Zhou

Qiangling Sun

Zhongliang Ma

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is one of the most malignant cancers threatening human health. The miR-17-92 gene cluster is a highly conserved oncogene cluster encoding 6 miRNAs: miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92a. This study explored whether these miRNAs can be used as diagnostic markers for non-small-cell lung cancer (NSCLC).

Methods: Serum samples were collected from healthy subjects (n = 23) and NSCLC patients at various stages (n = 74). Serum RNA was extracted by the TRIzol-glycogen method, and cDNA libraries were constructed by reverse transcription. Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to detect the expression levels of the 6 miRNAs.

Results: The expression levels of the 6 miRNAs varied in different stages of NSCLC. Thus, 2 receiver operating characteristic (ROC) curves, that is, normal subjects and stage I-III patients and normal subjects and stage IV patients, of each miRNA were established to determine the interval of normal ΔCt values. The 2 areas under the curve (AUCs) of each miRNA were investigated (miR-17: 0.8097 and 1.000; miR-18a: 0.7388 and 0.9907; miR-19a/19b: 0.8451 and 0.5104; miR-20a: 0.8975 and 1.000; miR-92a: 0.8097 and 0.8342). In addition, a high positive correlation was discovered between miR-17 and miR-20a expression. Combining these 2 miRNAs can improve the screening effect of NSCLC.

Conclusion: The miR-17-92 gene cluster can likely serve as a diagnostic marker in NSCLC.

Citing Articles

Enigmatic exosomal connection in lung cancer drug resistance.

Patra S, Sahoo R, Biswal S, Panda S, Biswal B Mol Ther Nucleic Acids. 2024; 35(2):102177.

PMID: 38617976 PMC: 11015513. DOI: 10.1016/j.omtn.2024.102177.

Therapeutic role of miR-19a/b protection from influenza virus infection in patients with coronary heart disease.

Xing Y, Chen L, Hu B, Li Y, Mai H, Li G Mol Ther Nucleic Acids. 2024; 35(1):102149.

PMID: 38435118 PMC: 10907223. DOI: 10.1016/j.omtn.2024.102149.

Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.

Sadeghi M, Lotfi M, Soltani N, Farmani E, Fernandez J, Akhlaghitehrani S Cancer Cell Int. 2023; 23(1):284.

PMID: 37986065 PMC: 10661689. DOI: 10.1186/s12935-023-03133-z.

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.

Garbo E, Del Rio B, Ferrari G, Cani M, Napoli V, Bertaglia V Cancers (Basel). 2023; 15(19).

PMID: 37835468 PMC: 10571819. DOI: 10.3390/cancers15194774.

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients.

Raczkowska J, Bielska A, Kretowski A, Niemira M Front Oncol. 2023; 13:1209299.

PMID: 37546401 PMC: 10401434. DOI: 10.3389/fonc.2023.1209299.

References

Li H, Wu Q, Li T, Liu C, Xue L, Ding J . The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review. Oncotarget. 2017; 8(28):45060-45071. PMC: 5542167. DOI: 10.18632/oncotarget.15023. View

Wang W, Yin Y, Shan X, Zhou X, Liu P, Cao Q . The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer. Am J Med Sci. 2019; 358(4):256-267. DOI: 10.1016/j.amjms.2019.07.005. View

Zhang X, Li Y, Qi P, Ma Z . Biology of MiR-17-92 Cluster and Its Progress in Lung Cancer. Int J Med Sci. 2018; 15(13):1443-1448. PMC: 6216058. DOI: 10.7150/ijms.27341. View

Huang Z, Zhu D, Wu L, He M, Zhou X, Zhang L . Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer. Cancer Epidemiol Biomarkers Prev. 2016; 26(2):188-196. DOI: 10.1158/1055-9965.EPI-16-0607. View

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

Zhang Y, Zhang Y, Yin Y, Li S . Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients. Pathol Res Pract. 2019; 215(8):152466. DOI: 10.1016/j.prp.2019.152466. View

Chen Z, Huang L, Zhu B . Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer. Dis Markers. 2019; 2018:9845123. PMC: 6311751. DOI: 10.1155/2018/9845123. View

Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y . Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer. Int J Biol Sci. 2019; 15(8):1712-1722. PMC: 6643220. DOI: 10.7150/ijbs.33986. View

Mendell J . miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008; 133(2):217-22. PMC: 2732113. DOI: 10.1016/j.cell.2008.04.001. View

10.

Bianchi F, Nicassio F, Marzi M, Belloni E, DallOlio V, Bernard L . A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011; 3(8):495-503. PMC: 3377091. DOI: 10.1002/emmm.201100154. View

11.

Wang L, Wang D, Zheng G, Yang Y, Du L, Dong Z . Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers. 2015; 31(1):e80-7. DOI: 10.5301/jbm.5000177. View

12.

Foshay K, Gallicano G . miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation. Dev Biol. 2008; 326(2):431-43. DOI: 10.1016/j.ydbio.2008.11.016. View

13.

Chu G, Lazare K, Sullivan F . Serum and blood based biomarkers for lung cancer screening: a systematic review. BMC Cancer. 2018; 18(1):181. PMC: 5812229. DOI: 10.1186/s12885-018-4024-3. View

14.

Jensen S, Lamy P, Rasmussen M, Ostenfeld M, Dyrskjot L, Orntoft T . Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics. 2011; 12:435. PMC: 3184117. DOI: 10.1186/1471-2164-12-435. View

15.

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F . A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6):R64. PMC: 2718498. DOI: 10.1186/gb-2009-10-6-r64. View

16.

Sourvinou I, Markou A, Lianidou E . Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn. 2013; 15(6):827-34. DOI: 10.1016/j.jmoldx.2013.07.005. View

17.

Zhu Y, Gu J, Li Y, Peng C, Shi M, Wang X . MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. Cancer Lett. 2017; 412:59-68. DOI: 10.1016/j.canlet.2017.09.044. View

18.

Liang C, Zhang X, Wang H, Liu X, Zhang X, Zheng B . MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis. 2017; 8(5):e2764. PMC: 5520692. DOI: 10.1038/cddis.2017.145. View

19.

Zhou P, Ma L, Zhou J, Jiang M, Rao E, Zhao Y . miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells. Int J Oncol. 2016; 48(4):1737-48. DOI: 10.3892/ijo.2016.3392. View

20.

Fang L, Wang X, Sun B, Zhang X, Zhu X, Yu Z . Expression, regulation and mechanism of action of the miR-17-92 cluster in tumor cells (Review). Int J Mol Med. 2017; 40(6):1624-1630. PMC: 5716450. DOI: 10.3892/ijmm.2017.3164. View